Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 10/20 | 0.56 |
| ▸ | NSD2 | O96028 | 3/20 | 0.51 |
| ▸ | RAF1 | P04049 | 7/20 | 0.49 |
| ▸ | BRAF | P15056 | 7/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25040262 | 0.85 | SETD2 (0.56) | SETD2NSD2LCLAT1 | |
| SCHEMBL25039743 | 0.83 | SETD2 (0.56) | SETD2NSD2BRAF | |
| SCHEMBL26100274 | 0.83 | SETD2 (0.56) | SETD2NSD2LCLAT1 | |
| SCHEMBL26098260 | 0.82 | SETD2 (0.55) | SETD2NSD2 | |
| SCHEMBL25039829 | 0.81 | SETD2 (0.63) | SETD2NSD2 | |
| SCHEMBL25040178 | 0.81 | SETD2 (0.59) | SETD2NSD2 | |
| SCHEMBL25040762 | 0.81 | SETD2 (0.59) | SETD2NSD2 | |
| SCHEMBL26097853 | 0.81 | SETD2 (0.55) | SETD2NSD2LCLAT1 | |
| SCHEMBL26098336 | 0.81 | SETD2 (0.56) | SETD2NSD2KAT6A | |
| SCHEMBL25040666 | 0.80 | SETD2 (0.58) | SETD2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | Epizyme, Inc. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| CN-112585119-A | Substituted indoles and methods of use thereof | EPIZYME股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | CCNE1, CCNE2, FOXM1 | SETD2 947/4885NSD2 641/4885RAF1 1135/4885 |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | FOXM1, CCNE2, CCNE1 | SETD2 1006/4885NSD2 644/4885RAF1 1352/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | SETD2 8/4885NSD2 6/4885RAF1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.